# Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults

> **NCT06842173** · PHASE1,PHASE2 · RECRUITING · sponsor: **Butantan Institute** · enrollment: 700 (estimated)

## Conditions studied

- Avian Influenza A Virus

## Interventions

- **BIOLOGICAL:** Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented, and Adjuvanted) 7.5 mcg
- **BIOLOGICAL:** Monovalent influenza vaccine type A (H5N8) 15 mcg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06842173
- **Lead sponsor:** Butantan Institute
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-10
- **Primary completion:** 2027-08-10
- **Final completion:** 2027-10-10
- **Target enrollment:** 700 (ESTIMATED)
- **Last updated:** 2026-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06842173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06842173, "Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06842173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*